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Purpose: To analyze functional and clinical data of Best vitelliform macular dystrophy (VMD) patients with mutations
in the BEST1 gene.
Methods: Best VMD patients with BEST1 mutations were evaluated prospectively regarding age, age of onset, best-
corrected visual acuity (BCVA), fundus autofluorescence, fluorescein angiography, optical coherence tomography, and
electro-oculography. Mutations in BEST1 were established by direct sequencing.
Results: Forty-six eyes of 23 patients (10 male, 13 female) were included in the study. We identified nine different
BEST1 mutations (3/9 novel), in ten unrelated families. The age of patients ranged between 3 and 75 years; age of onset
varied between 2 and 67 years. BCVA ranged between 20/20 and 20/200. On the basis of fundus biomicroscopy with
direct illumination, using one widely accepted classification, the macular lesions could be counted as follows: 1. no lesion
(normal fovea): eight eyes, five patients carrying a mutation on the BEST1 gene; 2. previtelliform lesions: six eyes, three
affected patients; 3. vitelliform lesions: four eyes, two affected patients; 4. pseudohypopyon: three eyes, three affected
patients; 5. vitelliruptive lesions (scrambled egg aspect with dispersion of the vitelliform material without sign of atrophy
or fibrosis): ten eyes, six affected patients; 6. atrophic lesions (atrophy with or without residual dispersed material): seven
eyes, five patients; 7. fibrotic lesions: eight eyes, five patients. Two patients presented unilateral Best VMD. Both eyes
of two patients presented multifocal Best VMD features on fundus examination. Six eyes of four patients have been treated
for  choroidal  neovascularization  by  thermic  photocoagulation  [one  eye],  photodynamic  therapy  [three  eyes],  and
intravitreal ranibizumab injection [two eyes]. Comparison of interfamilial and intrafamilial clinical data between patients
did not reveal differences in age, BCVA, and stage of the disease as evaluated by fundus autofluorescence, fluorescein
angiography, and optical coherence tomography (p>0.05). Mean BCVA impairment showed a statistically significant
correlation to a more advanced stage of the disease (p<0.001).
Conclusions: BEST1 mutations were not correlated with the severity of the functional and clinical data in the Best VMD
patients examined.
Vitelliform  macular  dystrophy  (VMD)  was  first
described  by  Friedrich  Best  in  1905  with  a  complete
description of the various stages of the disease from eight
related individuals [1]. VMD (OMIM 153700), also called
Best  disease,  has  an  autosomal  dominant  pattern  of
inheritance but with variable expressivity. The gene involved
in  Best  VMD,  called  BEST1,  has  been  mapped  on
chromosome 11q12-q13, cloned, and sequenced [2]. The 68-
kDa protein encoded by the BEST1 gene, named bestrophin-1
[3], is localized to the basolateral plasma membrane of the
retinal  pigment  epithelium  (RPE)  and  appears  to  exhibit
properties of Ca2+-activated Cl− channels [4]. More than 100
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disease-causing  mutations  in  BEST1  have  been  reported
(HGMD), with nearly all of those causing Best VMD affecting
single  amino  acids  at  one  of  66  different  positions  in
bestrophin-1. The onset of Best VMD is variable, having a
bimodal distribution with one maximum peak before puberty
and a second following puberty and extending through the
fifth decade of life [5]. Heterozygous mutations in BEST1 may
also  cause  the  adult  form  of  VMD,  autosomal  recessive
bestrophinopathies,  other  autosomal  dominant
bestrophinopathies, and rare vitreoretinochoroidopathy.
Best VMD is a clinically heterogeneous and pleomorphic
disease; usually it begins with symptoms of metamorphopsia,
blurred vision, and a decrease of central vision. Most cases
have a solitary lesion in the macula; others have multifocal
vitelliform lesions [6,7], which are mostly confined to the
posterior pole. Five stages have been described, based on
fundus  examination  [8]:  the  previtelliform  stage  (normal
macula or subtle RPE alterations), the vitelliform stage (well
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2960circumscribed 0.5- to 2-disc-diameter “egg-yolk” lesion), the
pseudohypopyon  stage  (the  yellow  material  accumulated
inferiorly), the vitelliruptive stage (partial resorption of the
material, scrambled-egg lesion), and the atrophic stage (final
macular atrophy). An aspect of fibrosis (elevated changes
from white to yellowish) can also be observed as an optional
way of evolution of VMD. This cicatricial aspect can appear
with or without occurrence of choroidal neovascularization
(CNV). There is a controversy about the chronological order
of the stages. According to some authors, the sequence of the
pseudohypopion/vitelliruptive stages may be reversed.
Abnormal  electro-oculogram  (EOG)  [9,10],  with  a
reduced  or  nondetectable  light-peak  to  dark-trough  ratio
(≤1.55), combined with a normal clinical electroretinogram
(ERG)  [11],  a  blockage  effect  by  vitelliform  material  on
fluorescein angiography [12], and autofluorescence from the
vitelliform  lesions7  are  helpful  for  diagnosis.  Spaide  and
associates illustrated by optical coherence tomography (OCT)
that the yellow vitelliform accumulates in the subretinal space
and on the outer retinal surface [13]. We recently reported on
the  high-definition  spectral  domain  optical  coherence
tomography (HD-OCT; OCT 4000 Cirrus; Humphrey-Zeiss,
San Leandro, CA) findings in all the progressive stages of the
disease, including the previtelliform (preclinical) stage [14,
15].
Our purpose in this study was to analyze the functional
and clinical data in Best VMD patients, issuing primarily from
one single family, according to the mutations in the BEST1
gene.
METHODS
Best VMD patients and relatives that presented consecutively
at the Créteil University Eye Clinic, Creteil, France, and at the
Foggia University Eye Clinic, Foggia, Italy were included in
this prospective study. The clinical diagnosis, based on one or
multiple subfoveal vitelliform lesions in at least one eye, was
confirmed by two observers (GQ, EHS). At least one affected
individual from each family was diagnosed by both EOG and
fundus  examination.  Informed  consent  was  obtained
according to approved protocols of the Paris XII University
and  Foggia  University  Institutional  Review  Boards,  in
agreement with the Declaration of Helsinki. The patients were
evaluated  based  on  age  and  age  of  onset  (age  at  initial
examination  for  visual  impairment),  and  all  underwent  a
complete ophthalmologic examination, including assessment
of best-corrected visual acuity (BCVA) measured at 4 m with
standard Early Treatment Diabetic Retinopathy Study charts,
fundus  biomicroscopy,  color  photography  of  the  fundus
(Topcon  TRC-50  retinal  camera,  Tokyo,  Japan),  fundus
autofluorescence  (FAF)  frames  (Heidelberg  Retina
Angiograph  II,  Heidelberg  Engineering,  Heidelberg,
Germany), and red-free and fluorescein angiography (FA)
frames  (Topcon  TRC-50  retinal  camera,  Tokyo,  Japan;
Heidelberg Retina Angiograph II, Heidelberg Engineering).
Recordings of EOG and ERG (in selected cases) were done
according  to  the  International  Society  for  Clinical
Electrophysiology  of  Vision  standard  [16,17].  OCT
examination was performed with time domain OCT (OCT
3000 Stratus, Humphrey-Zeiss) and spectral domain OCT
(HD-OCT, OCT 4000 Cirrus, Humphrey-Zeiss). All scans
were positioned within the macular area and throughout the
vitelliform lesions, based on color fundus photography and
FAF. For each scan the shape and reflectivity of the material,
its location, the reflectivity and appearance of the RPE, and
retinal changes were specified. The diagnosis of Best VMD
was based on the presence of large vitelliform or vitelliruptive
TABLE 1. PRIMER SEQUENCES AND PCR CONDITIONS.
Exon Sequence of primers Number of cycles Annealing temperature (°C)
2 F-AGTCTCAGCCATCTCCTCGC 35 62
R-TGGCCTGTCTGGAGCCTG
3 F-GGGACAGTCTCAGCCATCTC 35 60
R-CAGCTCCTCGTAGTCCTCC
4 F-AGAAAGCTGGAGGAGCCG 35 60
R-GCGGCAGCCCTGTCTGTAC
5 F-GGGGCAGGTGGTGTTCAGA 35 60
R-GGCAGCCTCACCAGCCTAG
6 F-GGGCAGGTGGTGTTCAGA 35 60
R-CCTTGGTCCTTCTAGCCTCAG
7 F-CATCCTGATTTCAGGGTTCC 35 60
R-CTCTGGCCATGCCTCCAG
8 F-AGCTGAGGTTTAAAGGGGGA 35 60
R-TCTCTTTGGGTCCACTTTGG
9 F-ACATACAAGGTCCTGCCTGG 35 60
R-GCATTAACTAGTGCTATTCTAAGTTCC
10 A F-GGTGTTGGTCCTTTGTCCAC 35 60
R-CTCTGGCATATCCGTCAGGT
10 B F-CTTCAAGTCTGCCCCACTGT 35 60
R-TAGGCTCAGAGCAAGGGAAG
11 F-CATTTTGGTATTTGAAATGAAGG 35 60
R-CCATTTGATTCAGGCTGTTG
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2961lesions and a reduced light rise in the EOG, with or without a
positive family history of the disease.
All patients were screened for mutations in the BEST1
gene by direct sequencing. Genomic DNA was submitted to
standard PCR, using intronic primers designed to flank the
coding  exons  (2–11)  and  exon–intron  boundaries  of  the
BEST1 gene (primer sequences and PCR conditions are listed
in  Table  1).  Amplified  products  were  directly  sequenced
without  preliminary  purification  using  the  Big  Dye
Terminator Cycle Sequencing kit v3.1 (Applied Biosystems,
Foster  City,  CA).  Sequenced  products  were  purified  by
exclusion chromatography (Sephadex G50; Sigma-Aldrich,
Saint Louis, MO), submitted to electrophoresis on an ABI
3130 automated sequencer (Applied Biosystems, Foster City,
CA), and data were analyzed using Sequencing Analysis v5.2
Software (Applied Biosystems). All exons were screened in
all probands. Segregation of the mutations with the disease
phenotype  was  established  by  using  the  available  family
members.  The  pathogenicity  of  unreported  nucleotide
changes was assessed by i) studying 96 unrelated control
individuals  (control  group)  matched  for  origin  with  no
personal or familial history of macular degeneration or retinal
dystrophy, and ii) applying the Polyphen (Harvard University,
Boston,  MA)  program,  which  predicts  possible  impact
(benign, possibly damaging, probably damaging or unknown)
of an amino acid substitution on the structure and function of
human proteins (as previously reported by Ramensky et al.
[18]).
Statistical analyses were performed using STATA 10 MP
(StataCorp LP, College Station, TX) for MacOs X. Serial
interfamilial  and  intrafamilial  comparisons  of  specific
BEST1 mutations and expressivity with respect to age, BCVA
converted to the logarithm of the minimum angle of resolution
(logMAR), and stage of the disease were performed using the
ANOVA  (ANOVA)  test.  The  chosen  level  of  statistical
significance was p<0.05. Of note, most of the Best VMD
Figure  1.  Pedigrees  of  the  families
studied and segregation of the VMD2
mutant alleles. White circles represent
unaffected  females,  filled  circles
affected  females,  white  squares
unaffected  males,  and  filled  squares
affected  males.  Deceased  individuals
are shown with a slanting line across the
symbol.
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2962patients analyzed for this study issued from one single family,
and it is probably a major limitation of any statistical analysis
to propose a severity scaling.
RESULTS
Genetic analysis: The screening of the 11 exons encoding
BEST1 in ten unrelated families (4/10 from Italy; 6/10 from
France; Figure 1) resulted in the identification of nine different
missense mutations clustered in exons 2, 4, and 7 (Table 2).
Six out of the nine mutations have been previously reported
to be common Best VMD mutations (p.A243V, p.R92G, p.
R92C, p.T91I, p.R25W, p.V9A). The remaining three changes
have not been reported elsewhere (p.T4A, p.G15D, p.I230T;
Figure 2) and were absent from 192 control chromosomes.
Interspecies Basic Local Alignment Search Tool (BLAST)
alignments showed that residues at positions 4, 15, and 230
are conserved in vertebrate and invertebrate species (Figure
3).  Simulation  for  functional  changes  by  a  structure
homology-based method using the Polyphen program resulted
in classifying the p.T4A and p.G15D changes as possibly
damaging (position-specific independent counts, PSIC=1.847
and  1.936,  respectively,  and  the  p.I230T  substitution  as
probably damaging (I230T; PSIC=2.181).
Segregation analyses were performed when possible. In
all families but one, available affected patients were shown to
be heterozygous for the mutation. In family FGIII, the affected
patient FG08 was apparently homozygous for the p.R92C
mutation.  Parental  DNA  samples  were  unavailable  to
determine between homozygosity and deletion at the BEST1
locus. This apparently homozygous p.R92C finding could
clearly  be  homozygous  or  could  reflect  a  combination
between a point mutation in one allele and a deletion in the
other  allele.  However,  homozygosity  is  probable  as  both
parents were born in the same village of the Puglia region in
Italy. Finally, that three unaffected individuals harbored the
pathogenic  mutation  identified  in  their  families  (patients
FG04, FG05, and FG10; Figure 4).
Finally, our data add another example of amino acid
residues that produce Best VMD when mutated to different
amino acids: arginine at position 92 was substituted by a
glycine in patient FG06 and patient FG07 (FAMILY FG II)
or by a cysteine in patient FG08 (FAMILY FG III) and patient
CT01 (FAMILY CT I).
Functional and clinical data: We examined 46 eyes of 23
patients harboring BEST1 mutations (10 male, 13 female).
Eighteen had Best VMD, two presented with multifocal Best
Figure 2. Electropherograms of the three
novel  BEST1  mutations.  These
electrophoregrams  show  an
heterozygous peak GA at position 44
responsible for a p.G15D mutation in
family FG IV, an heterozygous peak TC
at position 791 responsible for a p.I230T
mutation  in  family  CT  II,  and  an
heteozygous  peak  AG  at  position  10
responsible  for  a  p.T4A  mutation  in
family CT IV.
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2964VMD, and three were asymptomatic (Table 1). The mean age
of  patients  was  27.30  ±20.09  years.  Age  of  onset  varied
between  2  and  67  years  (median=13.5).  BCVA  ranged
between  20/20  and  20/200  (median,  20/35).  All  affected
patients had bilateral lesions except two unrelated patients
who had a unilateral lesion (CT07 aged 27 years and CT05
aged 70 years).
On  the  basis  of  fundus  biomicroscopy  with  direct
illumination  (performed  by  two  expert  retinal  physicians
[G.Q., E.H.S.]) and using one widely accepted classification,
the macular lesions could be counted as follows: 1. no lesion
(normal fovea): eight eyes, five patients carrying a mutation
on the BEST1 gene; 2. previtelliform lesions: six eyes, three
affected  patients;  3.  vitelliform  lesions:  four  eyes,  two
affected  patients;  4.  pseudohypopyon:  three  eyes,  three
affected  patients;  5.  vitelliruptive  lesions  (scrambled  egg
aspect with dispersion of the vitelliform material without sign
of  atrophy  or  fibrosis):  ten  eyes,  six  affected  patients;  6.
atrophic lesions (atrophy with or without residual dispersed
material): seven eyes, five patients; 7. fibrotic lesions: eight
eyes, five patients.
Early  stage  lesions  were  characterized  by  the
accumulation of yellowish material within the macula and
within and/or outside the macular area, giving an aspect of
foveal granularity (previtelliform lesions) or a typical well
circumscribed yellow “egg yolk” (vitelliform lesion). This
material  was  highly  autofluorescent.  On  OCT  scans  it
appeared as a hyper-reflective dome-shaped lesion located
between the hyporeflective outer nuclear layer and the hyper-
reflective RPE layer.
Later stages included pseudohypopyon and vitelliruptive
(scrambled  egg  aspect  with  dispersion  of  the  vitelliform
material without sign of atrophy or fibrosis) lesions that were
characterized by partial/complete resorption of the yellowish
material, which was replaced by a fluid component showing
no increased fluorescence on FAF and reflectivity on OCT
examination.  These  stages  were  characterized  by  loss  of
continuity and centrifugal and downward movement of the
lipofuscin-like material.
Late  lesions  were  characterized  by  partial/complete
atrophy  (with  or  without  residual  dispersed  material)  or
fibrosis  (with  no  detectable  active  CNV)  within  the  area
previously occupied by the yellowish material. FA showed
both masking effects, from accumulation of material, and
transmission defects, from resorption of material, with passive
leakage. The EOG showed an abnormal light-peak to dark-
trough ratio (<1.55) in all affected eyes.
Even with the same mutation, the age of onset and the
disease progression (stage of the disease and visual function)
were highly variable interfamilially and intrafamilially. The
heterozygous p.R92G and p.G15D mutations accounted for
the earliest disease manifestations in our series (at 2 years of
age,  patient  FG07,  FAMILY  FGII  and  patient  FG09,
FAMILY FG IV, respectively) or either a later onset (at the
Figure 3. Protein sequence alignments via Protein Basic Local Alignment Search Tool (BLASTP) of the regions of the human proteins of the
BEST family (BEST1–4) and of the BEST1 proteins containing the p.T4A, p.G15D, and p.I230T novel mutations. The residues at position
4, 15, and 230 are highly conserved from mammals to flies as well as in two-thirds of the human BEST proteins. Interestingly, when
nonconserved, the amino acids are replaced by residues of the same classes (neutral polar threonine at position 4 is changed to neutral polar
asparagine and serine in human BEST4 and worm BEST1 proteins, respectively; nonpolar uncharged glycine at position 15 is changed to
uncharged nonpolar phenylalanine in the human BEST3 and worm BEST1 sequences, respectively; neutral nonpolar isoleucine at position
230 is changed to valine in the human BEST3 and worm BEST1 proteins). Interestingly, the three novel BEST1 mutations reported here are
expected to change the polarity and/or the charge of the protein. The p.T4A mutation changes a polar to a nonpolar amino acid, while the
p.G15D and I230T mutations change nonpolar uncharged residues to polar acidic (aspartic acid) and neutral nonpolar (threonine) residues,
respectively.
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2965age of 11 years for patient FG06, FAMILY FGII [p.R92G])
or even no disease manifestation (at the age of 30 years for
patient FG10 FAMILY FG IV [p.G15D]), respectively.
On the other hand, the heterozygous p.R92G, p.R92C,
p.T91I, and p.T4A mutations resulted in CNV development
(which was treated by photodynamic therapy [both eyes of
FG06, right eye of CT01], intravitreal ranibizumab injection
[left  eye  of  CT01,  right  eye  of  CT06],  and  thermic
photocoagulation [extrafoveal CNV, left eye of CT08]).
Three cases harboring heterozygous BEST1 mutations in
two families showed normal fundus findings, OCT, and EOG
(FG04  and  FG05  [p.A243V],  FAMILY  FG  I  and  FG10
[p.G15D], Family FG IV). Two unrelated patients carrying
different mutations of exon 2 presented unilateral Best VMD
(CT07 [p.T4A, novel mutation] and CT11 [p.R25W] from
FAMILY CT IV and FAMILY CT V, respectively). Patient
CT03 (FAMILY CTII), heterozygous for the p.I230T novel
mutation, and patient FG08 (FAMILY FG III), homozygous
or hemizygous for the p.R92G mutation, presented bilateral
multifocal Best VMD features on fundus examination.
No association existed between the specific nature of
BEST1 mutations and expressivity in relation to age, BCVA,
and stage of the disease, as evaluated by FAF, FA, and OCT
(p>0.05).  Mean  BCVA  impairment  showed  a  statistically
significant correlation to a more advanced stage of the disease
(p<0.001), which was independent of patients’ age. Patient
FG07 (FAMILY FG II) and patient FG09 (FAMILY FG IV)
presented noticeable functional and clinical data in that they
were diagnosed at an early age—about 2 years of age with
typical  vitelliform  lesions  already  visible  in  funduscopic
examination (Figure 5). Moreover, patient FG10 from the
same family as patient FG09 (FAMILY FG IV) and harboring
the  same  heterozygous  BEST1  mutation,  showed  normal
fundus  findings,  OCT,  and  EOG  at  the  age  of  30  years.
FAMILY FG01 presented noticeable functional and clinical
data in that one family member (patient FG03) was diagnosed
at a late age (67 years), and two family members with the same
heterozygous BEST1 mutation p.A243V (patient FG04 and
patient FG05) showed normal fundus findings, OCT, and
EOG  at  the  age  of  13  and  17  years,  respectively.  Two
unrelated  cases  presented  with  the  previtelliform  stage  as
diagnosed  by  fundus  examination,  EOG,  and  OCT  [14]
(patient CT02, Family CT II and patient CT13, Family CT VI;
Figure 6 and Figure 7). One case (patient CT03, FAMILY CT
II) presented with the multifocal Best VMD features. The
other multifocal Best VMD case (patient FG08) carried a
homozygous BEST1 mutation (exon 4 p. R92C), the same as
the heterozygous one found in patient CT01 (Figure 8). Patient
CT07  from  FAMILY  CT  IV  (novel  mutations,  p.T4A)
presented an end-stage disease in one eye and no evidence of
the disease in the other eye.
Figure  4.  Spectral  domain  high-
definition  optical  coherence
tomography  and  electro-oculogram
findings of patient FG10, patient FG05
and  patient  FG04.  Spectral  domain
high-definition  optical  coherence
tomography  scan  of  the  right  eye  of
patient FG10 (A, upper panel) shows
normal  macular  findings.  Electro-
oculogram of the same eye (A, bottom
panel) shows the light-peak saccade not
uniform, being the light-peak to dark-
trough  ratio  overall  normal  (>1.55).
Electro-oculograms of the right eye of
patient FG05 (B), and of the left eye
patient FG04 (C), show normal light-
peak to dark-trough ratio (>1.55).
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2966DISCUSSION
The most determinant symptom of Best VMD is the abnormal
EOG with a reduced light-peak to dark-trough ratio combined
with a normal ERG [19,20]. Bestrophin 1, the 585-amino acid
protein encoded by the BEST1 gene [3], is a member of the
RFP-TM  family  of  proteins,  so  named  for  their  highly
Figure 5. Color fundus photographs, fundus autofluorescence frames and optical coherence tomography scans of patient FG07 and patient
FG09. Color fundus photographs shows typical vitelliform lesions within the macula of patient FG07 (A) and patient FG09 (B). These
vitelliform lesions appear highly autofluorescent on fundus autofluorescence (C, patient FG07; D, patient FG09), and as hyper-reflective
dome-shaped lesions located between the hyporeflective outer nuclear layer and the hyper reflective retinal pigment epithelium layer, on both
time domain optical coherence tomography (E, patient FG07) and spectral domain high-definition optical coherence tomography (F, patient
FG09) scans.
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2967conserved arginine, phenylalanine, proline motif [3,21,22],
which  appears  to  exhibit  properties  of  Ca2+-activated  Cl−
channels [4,23,24]. Bestrophin 1 does not appear to be the
channel itself but to act as a modulating subunit; thus channel
function would directly correlate to the involved mutation.
The apparent role of bestrophin 1 in the regulation of ion
transport  obviously  affects  the  light  peak  on  EOG;  it  is
unlikely that the light peak defect itself is the cause of vision
loss in Best VMD. Any connection between the light-peak
deficit in Best VMD and lipofuscin accumulation in the RPE
(the most common histopathologic finding in Best VMD) is
speculative.  However,  given  that  ion  transport  is  a
requirement  for  acidification  of  phagolysosomal
compartments and Ca2+ is a critical regulator of vesicle fusion,
either of the proposed functions of bestrophin 1, if impaired,
could lead to the accumulation of lipofuscin (and ultimately
cause vision loss from lipofuscin toxicity to photoreceptors).
To date more than 108 different BEST1 mutations have been
reported (see the Human Gene Mutation Database).
Here, we report three novel missense changes absent from
192  control  chromosomes.  All  three  affected  residues  are
conserved through evolution and were predicted by a structure
homology-based method to have an impact on the protein
(Figure 3). Two out of the three mutations occur in exon 2
Figure 6. Color fundus photographs and
spectral  domain  optical  coherence
tomography scans of patient CT02 and
patient  CT04.  A  normal  fovea  and  a
vitelliruptive macular lesion are shown
on color fundus photographs of patient
CT02  (A)  and  patient  CT04  (B),
respectively.  Spectral  domain  high-
definition  optical  coherence
tomography scan shows, in the macular
area of patient CT02, a thickening of the
layer  corresponding  to  the  junction
between the retinal pigment epithelium
(RPE)  and  the  interface  of  the  inner
segment  and  outer  segment  of  the
photoreceptor (C). An optically empty
lesion between the RPE and the inner
segment /outer segment interface, with
clumping  of  hyper-reflective  material
on the posterior retinal surface and, on
some parts, a hyper-reflective mottling
stuck on the RPE layer (D), appears on
the macular scan of patient CT04.
Figure 7. Color fundus photographs and
spectral  domain  optical  coherence
tomography scans of patient CT13 and
patient CT12. A normal fovea and an
atrophic macular lesion are shown on
color  fundus  photographs  of  patient
CT13  (A)  and  patient  CT04  (B),
respectively.  Spectral  domain  high-
definition  optical  coherence
tomography scan shows, in the macular
area of patient CT13, a thickening of the
layer  corresponding  to  the  junction
between the retinal pigment epithelium
(RPE)  and  the  interface  of  the  inner
segment  and  outer  segment  of  the
photoreceptor (C). A thinning of all the
retinal  layers  with  enhancement  of
reflectivity  of  RPE,  which  seems  to
spread far behind it (D), appears on the
macular scan of patients CT12.
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2968Figure 8. Color fundus photographs, fundus autofluorescence frames and spectral-domain optical coherence tomography scans of patient CT01
and patient FG08. Color fundus photographs show the fibrotic lesion of patient CT01 (A), characterized by an aspect of macular fibrosis
without any detectable active choroidal neovascularization, and the multifocal vitelliform lesions of patient FG08 (B), characterized by a
vitelliruptive aspect within the macular area. The fibrotic lesion of patient CT01 is responsible for reduced autofluorescence within the macula,
on fundus autofluorescence frames (C), as well as for a prominent hyper reflective thickening at the level of the retinal pigment epithelium
(RPE) inducing marked anterior bulging, accompanied by thinning of the sensory retina, on spectral domain high-definition optical coherence
tomography scan (E); the multifocal vitelliform lesions of patient FG08 are visualized as multiple hyperautofluorescent lesions, on fundus
autofluorescence frames, as well as an optically empty lesion between the RPE and the inner segment/outer segment interface, with clumping
of hyper-reflective material on the posterior retinal surface, on time domain optical coherence tomography scan (F).
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2969(p.T4A and p.G15D), which is located in the NH2 cytoplasmic
domain of the protein. Interestingly, it has been demonstrated
that the p.T6P and p.A10V mutations that affect this domain
produce currents with an amplitude >20% that of wild-type
bestrophin [25]. The novel mutations p.T4A and p.G15D are
predicted  to  change  the  polarity  and/or  the  charge  of  the
NH2 terminus of the protein and therefore may be regarded as
disease causing. The third novel mutation, p.I230T, may alter
the structure of the protein as it changes a hydrophobic residue
located in the transmembrane domain of the protein into a
polar residue.
Of note, the p.V9A change had previously been classified
as  a  change  of  uncertain  pathogenicity  seemingly
conservative by Petrukhin et al. [3]. In our study this change
was regarded as a disease-causing mutation by virtue of its
absence from 192 control chromosomes and its Polyphen
PSIC  score  (1.949),  which  suggests  that  it  may  have  a
functional impact.
Heterozygous mutations in BEST1, which usually cause
typical Best VMD, may also cause adult vitelliform macular
degeneration [26,27], autosomal dominant bestrophinopathy,
and a rare and unique condition called autosomal dominant
vitreoretinochoroidopathy [28]. Burgess et al. [29] recently
reported  on  compound  heterozygous  or  homozygous
mutations in the BEST1 gene as the causative mutations for a
distinctive  retinopathy,  which  they  named  autosomal-
recessive bestrophinopathy (ARB). Given that the different
diseases caused by BEST1 gene mutations may share common
clinical  findings,  a  complete  clinical  examination  of  Best
VMD patients combined with molecular genetics studies of
the BEST1 gene is mandatory for adequate counseling of the
families.  Interestingly,  while  in  nine  of  the  ten  pedigrees
reported  here  the  disease  segregated  as  an  autosomal
dominant trait, in one family the affected patient (FG08) was
apparently homozygous for a BEST1 mutation [p.R92C]. The
common origin of the patient’s parents’ homozygosity for the
mutation is the likely reason, although hemizygosity at the
BEST1 locus cannot be excluded. In any case, mutational
biallelism raises the question as to whether, instead of Best
VMD,  the  patient  may  be  affected  with  the  autosomal-
recessive bestrophinopathy described by Burgess et al. as a
null  phenotype  of  bestrophin-1  in  humans  [29].  Clinical
examination showed that the patient had no ARB-associated,
scattered, punctate flecks and retinal edema but presented with
bilateral multifocal lesions consistent with the diagnosis of
multifocal Best VMD. This phenotype may be considered
more severe than that of another patient heterozygous for the
p.R92C mutation who is affected with bilateral focal lesions
complicated by CNV. This observation differs from that of
Bakall et al. who reported on the histopathology of a donor
eye from an individual homozygous for the BEST1 p.W93C
mutation and concluded that the clinical and pathological
effects of homozygosity for the p.W93C mutation are not
more severe than those reported for heterozygotes [30].
In  our  series  we  report  a  large  interfamilial  and
intrafamilial  clinical  variability  in  terms  of  age  of  onset,
disease progression, stage of the lesions, and visual function.
We  found  no  association  between  BEST1  mutations  and
expressivity, with respect to age, BCVA, and stage of the
disease as evaluated by FAF, FA, and OCT. Mean BCVA
impairment showed a statistically significant correlation to a
more advanced stage of the disease. This association was
independent of the patients’ age. These data suggest that a
functional impairment in Best VMD may be related to the
progression  of  the  disease  rather  than  to  a  patient’s  age.
However, in the current series there was only one family to
illustrate  the  phenotype  of  each  mutation  except  for  one
mutation. This probably represents a major limitation of any
statistical analysis in proposing a severity scaling.
Interestingly, the p.A243V mutation was found to be
associated with late onset in one family of our Best VMD
series. This finding is consistent with a previous report of a
mild  and  relatively  invariable  Best  VMD  phenotype
associated with this mutation [31]. Even though our study was
not designed to investigate disease progression, the absence
of phenotype in two siblings of the same family harboring the
mutation may be explained by their young age (13 and 17
years). However, it is possible that these two individuals may
remain unaffected (normal fundus findings, OCT, and EOG)
through  their  life  span  as  well.  Incomplete  penetrance  is
indeed a well known feature in BEST1 disease. Functional
and clinical data in our series may support this notion. The
heterozygous p.R92G an p.G15D mutations resulted in the
earliest disease manifestation (at 2 years of age); however, the
same mutation was also responsible for either a later onset (at
the age of 11 years for FG06 [p.R92G]) or even no disease
manifestation (at the age of 30 years for FG10 [p.G15D])
within the same families (FAMILY FG II and FAMILY FG
IV, respectively).
All patients except two had bilateral macular lesions. Two
patients presented with unilateral disease, but this could not
be related either to their age or to their genotype. Indeed, one
of them, aged 27 (CT07), shared the p.T4A mutation with his
23-year-old sibling presenting with bilateral lesions (CT08).
Similarly,  the  second  patient,  a  70-year-old  man  (CT11)
carried the p.R25W mutation responsible for bilateral lesions
in two of his young relatives, aged 10 and 36. Similarly, CNV
did not appear to correlate with the mutation, as suggested by
the intrafamilial variability of this trait.
Bilateral multifocal Best VMD lesions were diagnosed at
the age of 41 in a patient heterozygous for another BEST1
mutation, p.I230T. Two younger relatives (aged 9 and 11)
presented with an early-stage lesion; progression is uncertain.
The  wide  variability  of  clinical  expression  of  BEST1
mutations  within  and  between  families  is  consistent  with
previous reports [27,32-40]. Owing to this wide variability of
clinical expression, it is difficult to compare our findings with
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2970other previously published series. Moreover, we adopted a
widely accepted clinical classification, and, based on fundus
biomicroscopy, all eyes were graded as showing only one of
the progressive stages of Best VMD; thus, for example, in
contrast  with  Boon  et  al.  [30],  we  did  not  consider
characteristics attributable to different stages. However, the
clinical features reported here for each progressive stage were
typical and actually consistent with other Best VMD series.
One limitation of the current study was the absence of
real  co-segregation  analysis  for  the  families  with  novel
reported changes. Another limitation was that we did not
perform, systematically, ERG in our patients and thus we were
not able to distinguish whether an abnormal light rise on EOG
would  have  been  due  to  either  photoreceptor  or  RPE
dysfunction.
Overall in our series, particularities were found in two
affected  patients  showing  unilateral  Best  VMD,  in  two
affected patients showing, in both eyes, multifocal Best VMD,
and in four affected patients (six eyes) who were treated for
CNV. All these are well known possible features of Best
VMD.  Three  out  of  23  patients  (13%)  with  the  BEST1
mutation showed normal fundus, OCT, and EOG findings.
In  conclusion,  variability  of  clinical  expression  of
BEST1 mutations suggests that cis or trans-acting genetic
modifiers may modulate the functional and clinical data.
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